Astrana Health Third Quarter 2026 Earnings Call - VITRIA TECHNOLOGY INC

Financial Performance:

• Q3 2026 revenue reached a record $1.02 billion, up 7% year-over-year (YoY).
• Adjusted EBITDA hit a record $77.2 million, up 13% YoY, landing near the high end of guidance.
• Adjusted diluted EPS was $0.71, with the 13% EBITDA growth driven organically.
• Capitation revenue grew 8.5% despite Medicaid and Exchange membership attrition.
• Free cash flow generation was strong, totaling approximately $105 million for the first nine months of 2026.
• Debt repayment of $116 million reduced net leverage to approximately 2.2x, ahead of acquisition commitments.
• Year-to-date General and Administrative (G&A) expenses declined to 6.2% of revenue, an 80 basis point improvement YoY.

Guidance and Future Outlook:

• Management expects at least mid-teens annual adjusted EBITDA growth for 2027.
• Medicare Advantage membership is projected to grow organically at a high single-digit rate in 2027; paid star ratings expected to improve modestly from 2026 levels.
• Medicare Advantage margins are forecasted to remain stable in 2027 despite potential impacts from excluded diagnosis sources.
• Medicaid membership is anticipated to decline 10% to 15% in 2027 due to policy changes (work requirements, redeterminations) and fee-for-service transitions.
• Exchange business attrition is expected to be more favorable than prior 30-40% assumptions, though the segment remains approximately 3% of revenue.
• Full-year 2027 G&A is expected to remain around 6.2% of revenue, with potential for further medium-term leverage as AI capabilities mature.

Business Segments and Product Lines:

• Total members under management ended the quarter at approximately 1.5 million.
• Medicare Advantage membership grew organically, countering industry-wide contraction trends.
• Full-risk arrangements now account for approximately 82% of capitation revenue, up from 76% at the end of 2025; Care Partners segment full-risk membership is at 46%.
• Launched "Atlas," a next-generation provider-facing platform helping physicians prioritize high-risk patients in real-time.
• Completed a tuck-in acquisition of an independent physician association in Georgia on October 1, 2026.
• Added new clients to the AI-powered care enablement platform, including a provider group in Connecticut and a hospital in California, both expected to onboard by early 2027.
• Entered into new Medicare Advantage partnerships effective January 1, 2027.

Market and Competitive Landscape:

• Texas market serves as a key proof point, with profitability improving faster than anticipated and medical cost trends running favorably to underwriting assumptions after transitioning 7,000+ members from GainShare to Global Risk.
• AstraNa's platform differentiates via a feedback loop of intelligence, alignment, and delivery, allowing for scalable market entry and accelerated path to profitability.
• Competition in the broader market involves health plans reducing Medicare Advantage footprints, whereas AstranaHealth is expanding its presence.
• The consolidated medical cost performance continues to outperform initial year-end expectations, despite pressures in Medicaid and commercial segments related to clinician-administered drug costs.

Risks and Challenges:

• Medicaid attrition is expected to be in the middle to high end of the 10-15% range initially assumed, driven by regulatory changes and eligibility redeterminations.
• Commercial medical cost trends are slightly above expectations, primarily driven by clinician-administered drug costs.
• Potential future uncertainties regarding Medicare Advantage rate notices and the exclusion of certain diagnosis sources, though currently deemed immaterial.
• Forward-looking statements remain subject to risks and uncertainties that could cause actual results to differ materially from projections.

Management Commentary and Tone:

• Management tone was confident and positive, emphasizing disciplined execution, margin expansion, and the maturation of the integrated operating platform.
• CEO Brandon Sim highlighted the "flywheel" effect of their platform capabilities (intelligence, alignment, delivery) as a key driver for reducing upfront market entry costs.
• CFO Chan Basho noted that the operational transformation regarding the Prospect acquisition is complete, with retention above 99% and synergy targets met.
• Management views the Prospect transaction as fully integrated into the core business rather than a separate initiative.

Analyst Questions and Answers:

• (Note: Specific Q&A details were not included in the provided transcript text; however, management proactively addressed common themes including Texas performance, Medicaid headwinds, and 2027 guidance during the prepared remarks.)
• Management addressed the stability of Medicare Advantage margins and the manageable nature of commercial cost pressures.
• Clarification was provided on the timeline for new client onboarding and the specific impact of policy changes on Medicaid membership for 2027.

Other Key Points:

• The company's "Pathways" care management platform coordinates interventions for high-risk conditions including congestive heart failure, COPD, and chronic kidney disease, with annual wellness visits reaching nearly 65% of eligible members.
• AI adoption has reduced claims handling times by over 50% and is currently being used to automate entire business processes, such as translating contract terms into claims configuration in minutes rather than hours.
• The company is reinvesting outperformance from strong operating results into new growth opportunities while maintaining balance sheet discipline.